Pharma Industry Encouraged to Adopt Mobile ePRO for Clinical Trials Efficiency at DIA 2014
News Jun 06, 2014
Exco InTouch is championing the industry to adopt mobile electronic Patient Reported Outcomes (ePRO) and other electronic Clinical Outcomes Assessments (eCOA) measures to ensure greater clinical trial success.
Currently, over 80% of clinical trials experience delays and mobile ePRO can help mitigate these risks by increasing trial efficiency and patient adherence.
Responding to this issue, Exco InTouch will deliver insights into the application of mobile solutions across the clinical research industry, at this year’s 50th annual DIA meeting, taking place 15th-19th June in San Diego.
Showcasing their position as the leader in the application of mobile in ePRO, the company will host on-site demonstrations and a series of 5 presentations, featuring industry-leading content from Tim Davis, CEO, Exco InTouch and Judith Teall, Director of Clinical Excellence.
For those looking to learn more about the high value that mobile technology can offer to clinical trials, presentations will include ‘Electronic Clinical Outcome Assessments: Coming to a Device Near You!’ and ‘The Use of Mobile Technology to Place Patients at the Center of Clinical Trials’.
Exco InTouch, which will be exhibiting at booth 2116, will also demonstrate its approach to BYOD (bring your own device) and, more broadly to data capture and patient engagement services across clinical research programs. By enhancing clinical outcomes through improved patient compliance and data capture, their solutions will enhance trial efficiencies - ultimately speeding up potential times to market.
Tim Davis, CEO and co-founder of Exco InTouch commented, “Our presence at the DIA annual meeting will enable us to showcase our strengths as the industry leaders of mobile technology applications within clinical trials and the ease in which our services successfully captures ePRO. We are very much aware of the importance of making the clinical trial process simple for patients, and our technology, which enables a BYOD approach where appropriate, helps further increase patient engagement.”
He continued, “The global pharma industry is increasingly looking at ways to ensure its trials are run on time and with greater adherence. I would encourage everyone who wants to learn more about the benefits of our approach and the instruments and technologies that we have to offer, to visit our booth at DIA (2116) where we would be delighted to demonstrate our services first hand”.
Researchers Develop New Method to Generate Human AntibodiesNews
Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.READ MORE
Large-Scale Production of Living Brain Cells Enables Entirely New ResearchNews
After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.READ MORE
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018